A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
exenatide once weekly
exenatide twice daily
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring diabetes, exenatide once weekly, Byetta, Amylin, Lilly, Bydureon
Eligibility Criteria
Inclusion Criteria:
- Has been diagnosed with type 2 diabetes mellitus
- Has hemoglobin-specific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at screening
- Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening
- Has been treated with diet and exercise alone or in combination with a stable regimen of metformin (MET), a sulfonylurea (SU), a thiazolidinedione (TZD), a combination of metformin and an SU, a combination of metformin and a TZD, or a combination of an SU and a TZD for a minimum of 2 months prior to screening
Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to screening:
- Hormone replacement therapy (female subjects)
- Oral contraceptives (female subjects)
- Antihypertensive agents
- Lipid-lowering agents
- Thyroid replacement therapy
- Antidepressant agents
- Drugs known to affect body weight, including prescription medications (e.g. orlistat [XENICAL®], sibutramine [MERIDIA®], topiramate [TOPAMAX®]) and over the counter antiobesity agents
Exclusion Criteria:
- Has ever been exposed to exenatide (exenatide once weekly [exenatide LAR], exenatide BID, BYETTA, or any other formulation) or any glucagon-like peptide-1 (GLP-1) analog
- Has received any investigational drug within one month (or five half-lives of the investigational drug, whichever is greater) of screening
Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications:
- Any dipeptidyl peptidase 4 (DPP-4) inhibitor within 3 months prior to screening
- Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of screening
- Insulin within 2 weeks of screening or for more than 1 week within 3 months of screening
- Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Outcomes
Primary Outcome Measures
Change in HbA1c From Baseline to Week 24
Change in HbA1c from baseline (Day 1) to Week 24 [Week 24 - Baseline].
Secondary Outcome Measures
Percentage of Subjects Achieving HbA1c Target of <7%
Percentages of subjects achieving HbA1c target value of <7% at Week 24.
Percentage of Subjects Achieving HbA1c Target of <=6.5%
Percentages of subjects achieving HbA1c target values of <=6.5% at Week 24.
Change in Fasting Plasma Glucose From Baseline to Week 24
Change in fasting plasma glucose from baseline (Day 1) to Week 24.
Percentage of Subjects Achieving Fasting Plasma Glucose Target of <=126 mg/dL
Percentages of subjects achieving fasting plasma glucose target of <=126 mg/dL at Week 24.
Change in Body Weight From Baseline to Week 24
Change in body weight from baseline (Day 1) to Week 24.
Change in Sitting Systolic Blood Pressure From Baseline to Week 24
Change in systolic blood pressure from baseline (Day 1) to Week 24.
Change in Sitting Diastolic Blood Pressure From Baseline to Week 24
Change in diastolic blood pressure from baseline (Day 1) to Week 24.
Change in Total Cholesterol From Baseline to Week 24
Change in total cholesterol from baseline (Day 1) to Week 24.
Change in High-density Lipoprotein (HDL) From Baseline to Week 24
Change in HDL from baseline (Day 1) to Week 24.
Ratio of Triglycerides at Week 24 to Baseline
Ratio of triglycerides (measured in mg/dL) at Week 24 to baseline (Day 1). Log (Postbaseline Triglycerides) - log (Baseline Triglycerides); change from baseline to endpoint is presented as ratio of endpoint to baseline.
Assessment on Event Rate of Treatment-emergent Major Hypoglycemic Events
The major hypoglycemia category included events that, in the judgment of the investigator or physician, resulted in loss of consciousness, seizure, coma, or other change in mental status consistent with neuroglycopenia, in which symptoms resolved after administration of intramuscular glucagon or intravenous glucose, required third-party assistance, and was accompanied by a blood glucose concentration of less than 54 mg/dL prior to treatment, whether or not symptoms of hypoglycemia were perceived by the subject.
Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events
The minor hypoglycemia category included events in which symptoms consistent with hypoglycemia were accompanied by a blood glucose concentration of less than 54 mg/dL prior to treatment and not classified as major hypoglycemia.
Full Information
NCT ID
NCT00877890
First Posted
April 6, 2009
Last Updated
March 19, 2015
Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
1. Study Identification
Unique Protocol Identification Number
NCT00877890
Brief Title
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
Official Title
A Randomized, Open-Label, Parallel-Group, Comparator-Controlled, Multicenter Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
October 2009 (Actual)
Study Completion Date
January 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
diabetes, exenatide once weekly, Byetta, Amylin, Lilly, Bydureon
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
254 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
exenatide once weekly
Other Intervention Name(s)
BYDUREON
Intervention Description
subcutaneous injection, 2.0mg, once a week
Intervention Type
Drug
Intervention Name(s)
exenatide twice daily
Other Intervention Name(s)
BYETTA
Intervention Description
subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
Primary Outcome Measure Information:
Title
Change in HbA1c From Baseline to Week 24
Description
Change in HbA1c from baseline (Day 1) to Week 24 [Week 24 - Baseline].
Time Frame
Day 1, Week 24
Secondary Outcome Measure Information:
Title
Percentage of Subjects Achieving HbA1c Target of <7%
Description
Percentages of subjects achieving HbA1c target value of <7% at Week 24.
Time Frame
Week 24
Title
Percentage of Subjects Achieving HbA1c Target of <=6.5%
Description
Percentages of subjects achieving HbA1c target values of <=6.5% at Week 24.
Time Frame
Week 24
Title
Change in Fasting Plasma Glucose From Baseline to Week 24
Description
Change in fasting plasma glucose from baseline (Day 1) to Week 24.
Time Frame
Day 1, Week 24
Title
Percentage of Subjects Achieving Fasting Plasma Glucose Target of <=126 mg/dL
Description
Percentages of subjects achieving fasting plasma glucose target of <=126 mg/dL at Week 24.
Time Frame
Week 24
Title
Change in Body Weight From Baseline to Week 24
Description
Change in body weight from baseline (Day 1) to Week 24.
Time Frame
Day 1, Week 24
Title
Change in Sitting Systolic Blood Pressure From Baseline to Week 24
Description
Change in systolic blood pressure from baseline (Day 1) to Week 24.
Time Frame
Day 1, Week 24
Title
Change in Sitting Diastolic Blood Pressure From Baseline to Week 24
Description
Change in diastolic blood pressure from baseline (Day 1) to Week 24.
Time Frame
Day 1, Week 24
Title
Change in Total Cholesterol From Baseline to Week 24
Description
Change in total cholesterol from baseline (Day 1) to Week 24.
Time Frame
Day 1, Week 24
Title
Change in High-density Lipoprotein (HDL) From Baseline to Week 24
Description
Change in HDL from baseline (Day 1) to Week 24.
Time Frame
Day 1, Week 24
Title
Ratio of Triglycerides at Week 24 to Baseline
Description
Ratio of triglycerides (measured in mg/dL) at Week 24 to baseline (Day 1). Log (Postbaseline Triglycerides) - log (Baseline Triglycerides); change from baseline to endpoint is presented as ratio of endpoint to baseline.
Time Frame
Day 1, Week 24
Title
Assessment on Event Rate of Treatment-emergent Major Hypoglycemic Events
Description
The major hypoglycemia category included events that, in the judgment of the investigator or physician, resulted in loss of consciousness, seizure, coma, or other change in mental status consistent with neuroglycopenia, in which symptoms resolved after administration of intramuscular glucagon or intravenous glucose, required third-party assistance, and was accompanied by a blood glucose concentration of less than 54 mg/dL prior to treatment, whether or not symptoms of hypoglycemia were perceived by the subject.
Time Frame
Day 1 to Week 24
Title
Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events
Description
The minor hypoglycemia category included events in which symptoms consistent with hypoglycemia were accompanied by a blood glucose concentration of less than 54 mg/dL prior to treatment and not classified as major hypoglycemia.
Time Frame
Day 1 to Week 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Has been diagnosed with type 2 diabetes mellitus
Has hemoglobin-specific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at screening
Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening
Has been treated with diet and exercise alone or in combination with a stable regimen of metformin (MET), a sulfonylurea (SU), a thiazolidinedione (TZD), a combination of metformin and an SU, a combination of metformin and a TZD, or a combination of an SU and a TZD for a minimum of 2 months prior to screening
Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to screening:
Hormone replacement therapy (female subjects)
Oral contraceptives (female subjects)
Antihypertensive agents
Lipid-lowering agents
Thyroid replacement therapy
Antidepressant agents
Drugs known to affect body weight, including prescription medications (e.g. orlistat [XENICAL®], sibutramine [MERIDIA®], topiramate [TOPAMAX®]) and over the counter antiobesity agents
Exclusion Criteria:
Has ever been exposed to exenatide (exenatide once weekly [exenatide LAR], exenatide BID, BYETTA, or any other formulation) or any glucagon-like peptide-1 (GLP-1) analog
Has received any investigational drug within one month (or five half-lives of the investigational drug, whichever is greater) of screening
Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications:
Any dipeptidyl peptidase 4 (DPP-4) inhibitor within 3 months prior to screening
Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of screening
Insulin within 2 weeks of screening or for more than 1 week within 3 months of screening
Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa Porter, MD
Organizational Affiliation
Amylin Pharmaceuticals, LLC.
Official's Role
Study Director
Facility Information:
Facility Name
Research Site
City
Birmingham
State/Province
Alabama
Country
United States
Facility Name
Research Site
City
Mesa
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
Peoria
State/Province
Arizona
Country
United States
Facility Name
Research Site
City
Artesia
State/Province
California
Country
United States
Facility Name
Research Site
City
Concord
State/Province
California
Country
United States
Facility Name
Research Site
City
Encino
State/Province
California
Country
United States
Facility Name
Research Site
City
Greenbrae
State/Province
California
Country
United States
Facility Name
Research Site
City
La Mesa
State/Province
California
Country
United States
Facility Name
Research Site
City
Walnut Creek
State/Province
California
Country
United States
Facility Name
Research Site
City
DeLand
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Hialeah
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Miami
State/Province
Florida
Country
United States
Facility Name
Research Site
City
New Port Richey
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Palm Harbor
State/Province
Florida
Country
United States
Facility Name
Research Site
City
Chicago
State/Province
Illinois
Country
United States
Facility Name
Research Site
City
Avon
State/Province
Indiana
Country
United States
Facility Name
Research Site
City
Evansville
State/Province
Indiana
Country
United States
Facility Name
Research Site
City
Lexington
State/Province
Kentucky
Country
United States
Facility Name
Research Site
City
Paducah
State/Province
Kentucky
Country
United States
Facility Name
Research Site
City
Detroit
State/Province
Michigan
Country
United States
Facility Name
Research Site
City
Edina
State/Province
Minnesota
Country
United States
Facility Name
Research Site
City
St. Louis
State/Province
Missouri
Country
United States
Facility Name
Research Site
City
Butte
State/Province
Montana
Country
United States
Facility Name
Research Site
City
New Hyde Park
State/Province
New York
Country
United States
Facility Name
Research Site
City
Rochester
State/Province
New York
Country
United States
Facility Name
Research Site
City
Raleigh
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Statesville
State/Province
North Carolina
Country
United States
Facility Name
Research Site
City
Cincinnati
State/Province
Ohio
Country
United States
Facility Name
Research Site
City
Delaware
State/Province
Ohio
Country
United States
Facility Name
Research Site
City
Mentor
State/Province
Ohio
Country
United States
Facility Name
Research Site
City
Eugene
State/Province
Oregon
Country
United States
Facility Name
Research Site
City
Rapid City
State/Province
South Dakota
Country
United States
Facility Name
Research Site
City
Austin
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Corpus Christi
State/Province
Texas
Country
United States
Facility Name
Research Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
Research Site
City
Burke
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Manassas
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Richmond
State/Province
Virginia
Country
United States
Facility Name
Research Site
City
Olympia
State/Province
Washington
Country
United States
Facility Name
Research Site
City
Spokane
State/Province
Washington
Country
United States
Facility Name
Research Site
City
Tacoma
State/Province
Washington
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
21307137
Citation
Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011 May;96(5):1301-10. doi: 10.1210/jc.2010-2081. Epub 2011 Feb 9.
Results Reference
result
PubMed Identifier
27146799
Citation
Blevins T, Ruggles J, Hardy E. Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment. Diabetes Ther. 2016 Jun;7(2):361-8. doi: 10.1007/s13300-016-0172-0. Epub 2016 May 5.
Results Reference
derived
PubMed Identifier
23748506
Citation
Grimm M, Han J, Weaver C, Griffin P, Schulteis CT, Dong H, Malloy J. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Postgrad Med. 2013 May;125(3):47-57. doi: 10.3810/pgm.2013.05.2660.
Results Reference
derived
PubMed Identifier
23039868
Citation
Peyrot M, Bushnell DM, Best JH, Martin ML, Cameron A, Patrick DL. Development and validation of the self-management profile for type 2 diabetes (SMP-T2D). Health Qual Life Outcomes. 2012 Oct 5;10:125. doi: 10.1186/1477-7525-10-125.
Results Reference
derived
PubMed Identifier
22236356
Citation
Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012 Jun;14(6):546-54. doi: 10.1111/j.1463-1326.2012.01561.x. Epub 2012 Feb 10.
Results Reference
derived
Learn more about this trial
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
We'll reach out to this number within 24 hrs